The company issued a more cautious outlook on top-line growth for 2026, citing challenging conditions in Germany and supply constraints for biosimilar drugs in European and international markets.
The company issued a more cautious outlook on top-line growth for 2026, citing challenging conditions in Germany and supply constraints for biosimilar drugs in European and international markets.